[b]I hate to advocate drugs, alcohol, violence, or insanity to anyone, but they've always worked for me.[/b]
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If Elite is able to bag even 1%-1.5% of $500 million which is very conservative they will bring in almost half of what the bring in now per year.
What's next on the approval list? NORCO....
6 ANDAs submitted to the FDA and 1 NDA. Approvals will come soon.
This is not garbage.
Pete.... what did I tell you! Right now I cannot buy more so price will continue going up. LOL
Such is life my friend.
You called a great entry price last week. Good call.
Best,
JJ
BTW, it's Dianne.
Cost advantage...… Duhhhhh~!
Click it or ticket. LOL
Thank you for that excellent post N2K. In reality I did not even think
Elite/SunGen could capture 8.7% of the market the first year. Was looking at more like a 5% capture rate.
The cost of generic issue is one I never really considered, but that is why this is your field of expertise. Bringing costs of generics down with a unique formulation has to be the answer. I did recall NH stating that this platform could be used with all generics and that it was a game changer. Did he say potential game changer? Not to my recollection. I recall the phrase game changer. So game changer in cost of the generic?
Maybe that could be a question for the CC. Please feel free to correct me if I'm wrong with the game changer portion of my post. Could go back to the CC from a year ago but I'm lazy and will rely on my memory unless someone says otherwise. Saw the Guliano Brothers right around the CC from this time last year and beer plus whiskey shots sharpens my memory.
Real good post N2K. Very informative. Cost!
One thing we know for sure, Elite/SunGen have an IR CNS and with this most recent extended release version. If Ritalin they have it covered with regard to timed release formulations.
Elite, SunGen File First Joint ANDA
For a generic version of an immediate release CNS stimulant
Elite Pharmaceuticals and SunGen Pharma File ANDA for Extended-Release CNS Stimulant
ARbigguy1 it is indeed amazing how the AI remains the same yet the formulation to tweek it in some way changes, and valuation of these new formulations continues.
Pete, mick, totally agree with that. Cannot beat these prices.
Noticed that accumulation/distribution is almost going straight up.
Accumulators are excited, that's for sure.
Still waiting for my other, would like nothing more than to buy at these levels. When I'm ready to jump in that is when she moves. Such is my so called life...…. Phase 2b coming.
Elite has much experience with Ritalin. From what I understood Mehta brokered the Ritalin technology into ~$700 million. Seemed like a lot of money back then, but remember this, they had no steady revenue stream to help support the company like the generics they have today Makes too much sense for it not to Ritalin. Back then Elite had come up with a pulse technology. SunGen's platform is a gamechanger not just for Ritalin, but for all generic drugs across the board.
NH one smart cookie.
Of course if one knew anything about Elite they would have realized this
when NASDAQ brought it up. Question is, what technological advantage does SunGen have in their PIP that may be a game changer? And there is a very good chance that Elite/SunGen could take market share if this $1.6 billion space for this ONE CNS drug. SunGen's platform is game changing...….
Feel free to answer one and all...… should be good for a few laughs!
From 2000
Elite's Atul M. Mehta was recently issued a U.S. patent (No. 5,837,284) related to pulse dose methylphenidate products. The patent was exclusively licensed to Celgene Corp. (Warren, NJ), who then licensed the product to Novartis (see related article). Elite retains certain manufacturing rights for the patented product—which simulates two doses of the drug marketed as Ritalin—and also retained rights to its pulse dose technology as it relates to all non-methylphenidate drugs.
Hmmmmmmm interesting stuff alright! gggggg
This Avatar formulation will use SunGen's proprietary platform, as well as any of the formulations Elite/SunGen collaborate on.
So, what will differentiate this formulation from what is currently on the market? Stay tuned.
Say it ain't so~! LOL
Nonsense. Post the proof. Thanks in advance.
Absolutely false, inaccurate, and misleading. No investigations are going on at Elite.
If so.....just post the proof.
Support which was dismal at $0.08 is now pretty strong at $0.09.
All in a matter of a day. Could not push it below $0.08 despite
no news. $0.05 isn't coming anytime soon, but try to push it down for giggles.
LOL
Not true..... those who have been in the stock know that PMCB attracts
savvy investors with an eye toward the future of medical delivery technology. But will give a gold star for trying...…….
NASDAQ I keep mentioning SunGen's proprietary technology but folks just aren't listening. Guess we will have to let this formulation speak for itself when the time comes.
Actually Conix you're wrong on that. The fact that Elite has 5 ANDAs submitted plus 1 NDA submitted is very positive.
Elite's technologies will be a significant pipeline for any companies interested in adding it to their current pipeline. The Elite/SunGen formulations will be using SunGen's PIP, so those that say these formulations will not make a dent in current markets could be wrong.
Proof of concept is all that Elite needs right now. That proof of concept will come with approvals. So, we wait for the FDA.
Could very well be YJ4LIFE.
1000 x $8.50 = $85.00 even better.......
Hey ya just never know in this fickle market. Stranger things have happened.
100 X 0.085 = $8.50, still well short of $8.75 target set by the Redeye guy. But I'll take it.
Purdue's flunkies couldn't solve their own ADF issues and had the chance to grab Elite's ADF technology for next to nothing and failed to do so.
Why?
Because Purdue thought they had the situation in hand, when all along it was Elite that had the right polymer... not Purdue.... Oppppsy!
Then Purdue developed OxyContin..... the abuse resistant hard turtle shell
formulation that can easily be abused. Elite has a solution for that as well.... Elite's own version which already has been submitted to the FDA.
Nice try Purdue. Strike two...... next strike you are OUT!
But let's not forget that Purdue is tapping into markets outside of the US under another pharmaceutical name. Same company different name exploiting
people and markets outside of the US with their non ADF garbage.
When it comes to making money anyway they can without regard for safety
we can always count on that company to do what it can for themselves.
Just one approval will more than likely do it.
A few approvals will be awesome as revenues ramp UP.
Gottlieb was supposed to be the answer to get ANDAs approved faster. I see no evidence of that and think that was all smoke and mirrors. Same old FDA.
Troxyca approved yet can be abused with common chemicals. Why didn't the FDA see this? Now years after approval by the FDA this sort of breach in the formulation is found? Total bullshit and again because it was Pfizer, a trusted name in pharmaceuticals, Pfizer was granted approval. Why didn't the FDA do their diligence with Pfizer as they do with other companies?
Money screams volumes.........
LOL toofun. Good post that sums it up well.
Hopefully Elite doesn't have to do another fed BE study for SequestOx, but chances are pretty good they may have to.
And the timelines for all ANDAs submitted are guestimates. So far this FDA
under Gottlieb is no different than the FDA under Califf.
So Elite has had to do a cut tablet stability on Percocet. Norco was also mentioned, but Elite has decided to pass on Norco for now while addressing
the current ANDA Elite/SunGen will be submitting.
That will make 6 ANDAs and one NDA.
Yes, let's get this straight once and for all, sloppy Pfizer can't get a reliable ADF out on the market after spending 10s or hundreds of millions
on their formulations.... yet little itty bitty Elite can and will.
I agree... pretty unbelievable.
Me at whatever NH decides to sell the company for.